MHC Class II is Induced by IFNγ and Follows Three Distinct Patterns of Expression in Colorectal Cancer Organoids.


Journal

Cancer research communications
ISSN: 2767-9764
Titre abrégé: Cancer Res Commun
Pays: United States
ID NLM: 9918281580506676

Informations de publication

Date de publication:
08 2023
Historique:
received: 24 02 2023
revised: 17 05 2023
accepted: 05 07 2023
medline: 14 8 2023
pubmed: 11 8 2023
entrez: 11 8 2023
Statut: epublish

Résumé

Tumor-specific MHC class II (tsMHC-II) expression impacts tumor microenvironmental immunity. tsMHC-II positive cancer cells may act as surrogate antigen-presenting cells and targets for CD4 Cancer cell expression of MHC class II significantly impacts tumor microenvironmental immunity. Previous studies investigating mechanisms of repression of IFNγ-inducible class II expression using cell lines demonstrate epigenetic silencing of IFN pathway genes as a frequent immune evasion strategy. Unlike cell lines, patient-derived organoids maintain epigenetic fidelity to tissue of origin. In the first such study, we analyze patterns, dynamics, and epigenetic control of IFNγ-induced class II expression in a series of colorectal cancer organoids.

Identifiants

pubmed: 37565053
doi: 10.1158/2767-9764.CRC-23-0091
pii: CRC-23-0091
pmc: PMC10411481
doi:

Substances chimiques

Interferon-gamma 82115-62-6

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

1501-1513

Informations de copyright

© 2023 The Authors; Published by the American Association for Cancer Research.

Références

Oncogene. 2004 Nov 25;23(55):8876-86
pubmed: 15467734
Cancer Res. 2016 Jan 15;76(2):275-82
pubmed: 26567139
Nature. 2020 Aug;584(7822):624-629
pubmed: 32788723
Blood. 2007 Feb 1;109(3):1123-30
pubmed: 17008546
Cell. 2012 Jun 8;149(6):1192-205
pubmed: 22682243
Int J Cancer. 2012 Aug 15;131(4):E437-48
pubmed: 21989738
Front Immunol. 2019 Jul 30;10:1806
pubmed: 31417570
Nature. 2015 Jul 9;523(7559):231-5
pubmed: 25970248
Clin Epigenetics. 2022 Jan 6;14(1):3
pubmed: 34991708
Cancer Cell. 2019 Oct 14;36(4):385-401.e8
pubmed: 31564637
Clin Cancer Res. 2017 Sep 1;23(17):5187-5201
pubmed: 28698201
Oncotarget. 2016 Oct 25;7(43):69816-69828
pubmed: 27634879
Cancer Res. 2019 Apr 15;79(8):2009-2020
pubmed: 30737232
Eur J Immunol. 2003 May;33(5):1183-92
pubmed: 12731043
Hum Mol Genet. 2001 Jun 15;10(13):1413-9
pubmed: 11440994
Sci Adv. 2022 Oct 7;8(40):eabo8043
pubmed: 36197969
Genome Res. 2018 Nov;28(11):1747-1756
pubmed: 30341162
Oncogenesis. 2013 Sep 16;2:e71
pubmed: 24042735
Int J Cancer. 2002 Feb 1;97(4):501-7
pubmed: 11802213
Gastroenterology. 2011 Nov;141(5):1762-72
pubmed: 21889923
Sci Rep. 2017 Nov 30;7(1):16618
pubmed: 29192179
OMICS. 2012 May;16(5):284-7
pubmed: 22455463
Nat Immunol. 2016 Jan;17(1):95-103
pubmed: 26523864
Nat Genet. 1999 Dec;23(4):474-8
pubmed: 10581039
Int Immunol. 2009 Jun;21(6):655-65
pubmed: 19395374
Cancer Immunol Immunother. 2018 Mar;67(3):381-392
pubmed: 29124315
Genome Biol. 2022 Apr 28;23(1):106
pubmed: 35484598
Br J Cancer. 2002 Sep 23;87(7):756-62
pubmed: 12232760
Oncoimmunology. 2016 Nov 28;6(1):e1261777
pubmed: 28197387
PLoS One. 2017 Nov 9;12(11):e0176181
pubmed: 29121062
Gut. 2019 Jan;68(1):49-61
pubmed: 29141958
Sci Adv. 2021 Feb 26;7(9):
pubmed: 33637530
Clin Cancer Res. 2007 Jul 1;13(13):3933-41
pubmed: 17606727
BMC Bioinformatics. 2009 May 27;10:161
pubmed: 19473525
Cell. 2015 May 7;161(4):933-45
pubmed: 25957691
J Immunol. 2020 Apr 15;204(8):2295-2307
pubmed: 32179637
Cancer Discov. 2012 May;2(5):401-4
pubmed: 22588877
Clin Cancer Res. 2006 Jun 1;12(11 Pt 1):3435-43
pubmed: 16740768
Sci Transl Med. 2020 Oct 14;12(565):
pubmed: 33055240
Gastroenterology. 2000 Dec;119(6):1548-59
pubmed: 11113076
Bioinformatics. 2013 Jul 15;29(14):1830-1
pubmed: 23740750
Proc Natl Acad Sci U S A. 2014 Aug 12;111(32):11774-9
pubmed: 25071169
Clin Epigenetics. 2023 Apr 29;15(1):74
pubmed: 37120591
Nature. 2012 Jul 18;487(7407):330-7
pubmed: 22810696
J Immunol. 2007 Oct 15;179(8):5317-25
pubmed: 17911618
Sci Signal. 2013 Apr 02;6(269):pl1
pubmed: 23550210
Cell. 2020 Jun 25;181(7):1612-1625.e13
pubmed: 32497499
Clin Cancer Res. 2018 Feb 15;24(4):794-806
pubmed: 29242316
Cancer Res. 2002 Dec 15;62(24):7213-8
pubmed: 12499261
J Clin Invest. 1997 Jul 1;100(1):204-15
pubmed: 9202073
PLoS One. 2012;7(4):e36013
pubmed: 22563434
N Engl J Med. 2016 Sep 1;375(9):819-29
pubmed: 27433843
Int J Cancer. 2010 Aug 15;127(4):889-98
pubmed: 20013806
Nat Rev Immunol. 2018 Oct;18(10):635-647
pubmed: 30057419
Cell. 2018 Feb 22;172(5):1022-1037.e14
pubmed: 29429633
Immunity. 2018 Dec 18;49(6):1148-1161.e7
pubmed: 30552023
Br J Cancer. 2003 Feb 10;88(3):413-9
pubmed: 12569385

Auteurs

Oliver J Pickles (OJ)

Institute of Immunology and Immunotherapy, College of Medical and Dental Science, University of Birmingham, Edgbaston, Birmingham, United Kingdom.
University Hospitals Birmingham NHS Foundation Trust, Birmingham, United Kingdom.

Kasun Wanigasooriya (K)

Institute of Cancer and Genomic Science, College of Medical and Dental Science, University of Birmingham, Edgbaston, Birmingham, United Kingdom.

Anetta Ptasinska (A)

Institute of Cancer and Genomic Science, College of Medical and Dental Science, University of Birmingham, Edgbaston, Birmingham, United Kingdom.

Akshay J Patel (AJ)

Institute of Immunology and Immunotherapy, College of Medical and Dental Science, University of Birmingham, Edgbaston, Birmingham, United Kingdom.
University Hospitals Birmingham NHS Foundation Trust, Birmingham, United Kingdom.

Helen L Robbins (HL)

Institute of Immunology and Immunotherapy, College of Medical and Dental Science, University of Birmingham, Edgbaston, Birmingham, United Kingdom.

Claire Bryer (C)

Institute of Cancer and Genomic Science, College of Medical and Dental Science, University of Birmingham, Edgbaston, Birmingham, United Kingdom.

Celina M Whalley (CM)

Institute of Cancer and Genomic Science, College of Medical and Dental Science, University of Birmingham, Edgbaston, Birmingham, United Kingdom.

Louise Tee (L)

Institute of Cancer and Genomic Science, College of Medical and Dental Science, University of Birmingham, Edgbaston, Birmingham, United Kingdom.

Neeraj Lal (N)

Institute of Cancer and Genomic Science, College of Medical and Dental Science, University of Birmingham, Edgbaston, Birmingham, United Kingdom.

Claudia M A Pinna (CMA)

Institute of Cancer and Genomic Science, College of Medical and Dental Science, University of Birmingham, Edgbaston, Birmingham, United Kingdom.

Nahla Elzefzafy (N)

Institute of Cancer and Genomic Science, College of Medical and Dental Science, University of Birmingham, Edgbaston, Birmingham, United Kingdom.
Cancer Biology Department, NCI, Cairo University, Cairo, Egypt.

Philippe Taniere (P)

University Hospitals Birmingham NHS Foundation Trust, Birmingham, United Kingdom.

Andrew D Beggs (AD)

University Hospitals Birmingham NHS Foundation Trust, Birmingham, United Kingdom.
Institute of Cancer and Genomic Science, College of Medical and Dental Science, University of Birmingham, Edgbaston, Birmingham, United Kingdom.

Gary M Middleton (GM)

Institute of Immunology and Immunotherapy, College of Medical and Dental Science, University of Birmingham, Edgbaston, Birmingham, United Kingdom.
University Hospitals Birmingham NHS Foundation Trust, Birmingham, United Kingdom.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH